<DOC>
	<DOCNO>NCT02149537</DOCNO>
	<brief_summary>The vast majority birth sickle cell disease ( SCD ) occur Africa 90 % thought die age five . Hydroxyurea ( HU ) drug approve FDA treatment sickle cell anemia . Although HU use treat small number patient Africa , cost , fear toxicity , lack awareness availability limit use . The leukopenia may see HU raise possibility increase susceptibility infection . Risk stratification - i.e. , identification patient likely benefit- could focus therapy provide confidence risk : benefit ratio favorable . Several clinical measure future risk well defined finding modifier gene US , primarily relate fetal hemoglobin ( HbF ) , improve risk prediction . Whether genetic variant predict severity Africa know . The investigator establish SCD cohort Ibadan , Nigeria . In first phase research investigator implement clinical risk examination assess relationship clinical characteristic ( include level HbF ) know genetic marker . As proxy birth cohort , investigator compare frequency genetic marker adult patient ( i.e. , `` survivor '' ) child . In second phase investigator randomize 40 high risk adult patient fix low dose HU HU treatment crossover design monitor hematologic physiologic parameter document hematologic effect safety . This work lay basis large-scale trial document safety efficacy .</brief_summary>
	<brief_title>Risk Clinical Stratification Sickle Cell Disease Nigeria , Assessment Efficacy/Safety Hydroxyurea Treatment</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Age &gt; = 18 year HemoglobinSS ( HbSS ) betazero ( B0 ) thalassemia genotype Hemoglobin concentration &gt; 4.5 g/dL steady state time enrollment Absolute neutrophil count &gt; 1,500/mircoliter Platelet count &gt; 95,000/microliter Serum creatinine &lt; 1.2 mg/dL Alanine transaminase less two time upper limit normal HIVpositive Hepatitis B and/or C positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>sickle cell anemia</keyword>
	<keyword>hydroxyurea</keyword>
	<keyword>Nigeria</keyword>
	<keyword>low income country</keyword>
	<keyword>middle income country</keyword>
	<keyword>develop country</keyword>
</DOC>